Arcus Biosciences, Inc.
3928 Point Eden Way, Hayward, CA 94545
1800 Sierra Point Parkway, Brisbane, CA 94005
United States
186 articles about Arcus Biosciences, Inc.
-
Arcus Biosciences Announces New Employment Inducement Grants - April 25, 2023
4/25/2023
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 17,600 shares of the Company’s common stock at an exercise price per share of $19.31, which was the closing price on April 24, 2023, and restricted stock units to acquire a total of 8,800 shares of the Company’s common stock.
-
Arcus Biosciences Announces New Employment Inducement Grants - April 11, 2023
4/11/2023
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted nine new employees options to purchase a total of 34,000 shares of the Company’s common stock at an exercise price per share of $17.36, which was the closing price on April 10, 2023, and restricted stock units to acquire a total of 15,200 shares of the Company’s common stock.
-
Arcus Biosciences Announces New Employment Inducement Grants - March 9, 2023
3/9/2023
Arcus Biosciences, Inc. today announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 66,200 shares of the Company’s common stock.
-
Arcus Biosciences to Participate in the Barclays Global Healthcare Conference 2023
3/2/2023
Arcus Biosciences, a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Barclays Global Healthcare Conference in Miami Beach, Florida.
-
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update
2/28/2023
Arcus Biosciences, Inc. (NYSE:RCUS) today reported financial results for the fourth-quarter and full-year ended December 31, 2022 and provided a pipeline update on its six clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple common cancers.
-
Arcus Biosciences Announces New Employment Inducement Grants - February 24, 2023
2/24/2023
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 7,000 shares of the Company’s common stock at an exercise price per share of $18.66, which was the closing price on February 23, 2023, and restricted stock units to acquire a total of 3,500 shares of the Company’s common stock.
-
Arcus Biosciences Announces New Employment Inducement Grants - February 09, 2023
2/9/2023
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 31,600 shares of the Company’s common stock at an exercise price per share of $20.68, which was the closing price on February 8, 2023, and restricted stock units to acquire a total of 15,800 shares of the Company’s common stock.
-
Arcus Biosciences Announces New Employment Inducement Grants - Jan 24, 2023
1/24/2023
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 44,300 shares of the Company’s common stock at an exercise price per share of $22.02, which was the closing price on January 23, 2023, and restricted stock units to acquire a total of 22,150 shares of the Company’s common stock.
-
Arcus Biosciences Announces New Employment Inducement Grants - January 10, 2023
1/10/2023
Arcus Biosciences, Inc. today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 1,450 shares of the Company’s common stock at an exercise price per share of $17.51, which was the closing price on January 9, 2023.
-
Arcus Biosciences Announces New Employment Inducement Grants - December 24, 2022
12/24/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 11,250 shares of the Company’s common stock at an exercise price per share of $20.41, which was the closing price on December 23, 2022, and restricted stock units to acquire a total of 5,625 shares of the Company’s common stock.
-
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
12/19/2022
Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations.
-
Arcus Biosciences Announces New Employment Inducement Grants - December 9, 2022
12/9/2022
Arcus Biosciences, Inc. today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 8,200 shares of the Company’s common stock.
-
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer
11/28/2022
Gilead Sciences, Inc. and Arcus Biosciences announced a positive update from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations.
-
Arcus Biosciences Announces New Employment Inducement Grants - November 24, 2022
11/24/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted seven new employees options to purchase a total of 11,400 shares of the Company’s common stock at an exercise price per share of $27.17, which was the closing price on November 23, 2022, and restricted stock units to acquire a total of 5,700 shares of the Company’s common stock.
-
Arcus Biosciences to Participate in the 5th Annual Evercore ISI HealthCONx Conference
11/14/2022
Arcus Biosciences announced that its management team will participate in a virtual fireside chat at the upcoming 5th Annual Evercore ISI HealthCONx Conference.
-
Arcus Biosciences Announces New Employment Inducement Grants - November 09, 2022
11/9/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted nine new employees options to purchase a total of 13,700 shares of the Company’s common stock at an exercise price per share of $24.69, which was the closing price on November 8, 2022, and restricted stock units to acquire a total of 6,850 shares of the Company’s common stock.
-
Arcus Biosciences and its collaboration partner Gilead Sciences announced during Arcus’ third-quarter report that the company had modified its ARC-10 Phase III trial. -
Arcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update
11/2/2022
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the third quarter ended September 30, 2022 and provided a pipeline update on its six clinical-stage molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b), HIF-2a and PD-1 – across multiple common cancers.
-
Arcus Biosciences Announces New Employment Inducement Grants - October 25, 2022
10/25/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 9,100 shares of the Company’s common stock at an exercise price per share of $27.80, which was the closing price on October 24, 2022, and restricted stock units to acquire a total of 4,550 shares of the Company’s common stock.
-
Bay Area Biotech Companies Hiring Now
10/19/2022
The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here's a look at a few of the bay area biotech companies hiring now.